Figures computed from official regulatory filings — .
Analysttarget 10.4 USD (+137%) · consensus 4.8/5 · 5 buy · 0 hold · 0 sell
Ownershipinsiders 33.96% · institutions 35.73% · short 7.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for TriSalus Life Sciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
28 buys22 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Patience David | Other | $65.3K | SEC |
| Szela Mary Ttrack record | Award | $15K | SEC |
| Marshak Richard | Award | $2K | SEC |
| Marshak Richard | Award | $1.3K | SEC |
| Marshak Richard | Award | $2.2K | SEC |
| Szela Mary Ttrack record | Award | $12K | Unusual size | SEC |
| Szela Mary Ttrack record | Award | $15.4K | Unusual size | SEC |
| Marshak Richard | Award | $3.9K | SEC |
| Marshak Richard | Award | $4.3K | Unusual size | SEC |
| Szela Mary Ttrack record | Award | $9.2K | SEC |
| Marshall Richard Henry | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marshall Richard Henry | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marshak Richard | Sell | $1.4K | SEC |
| Szela Mary Ttrack record | Buy | $102.8K | conv 58Cluster | SEC |
| Stansky Michael Ptrack record | Buy | $500K | conv 63Cluster | SEC |
| Stansky Michael Ptrack record | Buy | $1M | conv 56Cluster | SEC |
| Wahlstrom Matstrack record | Buy | $151.8K | conv 63ClusterFirst in 12mo | SEC |
| Gordon Gary B. | Buy | $24.6K | conv 59Cluster | SEC |
| Patience David | Buy | $17.3K | conv 66Cluster | SEC |
| Gordon Gary B. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gordon Gary B. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stansky Michael Ptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stansky Michael Ptrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MATLIN DAVID Jtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Valle William | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |